Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study
Abstract Background Whether pre-diabetes in the absence of hypertension (HTN) or dyslipidemia (DLP) is a risk factor for occurrence of major adverse cardiovascular events (MACE) is not fully established. We investigated the effect of impaired fasting glucose (IFG) alone and in combination with HTN,...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-03-01
|
Series: | BMC Cardiovascular Disorders |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12872-020-01390-8 |
id |
doaj-347732ae67b64224ab31e1d817d5c30d |
---|---|
record_format |
Article |
spelling |
doaj-347732ae67b64224ab31e1d817d5c30d2020-11-25T03:25:08ZengBMCBMC Cardiovascular Disorders1471-22612020-03-0120111110.1186/s12872-020-01390-8Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort studyNahid Hashemi Madani0Faramarz Ismail-Beigi1Hossein Poustchi2Mahdi Nalini3Sadaf G. Sepanlou4Mojtaba Malek5Mohammad Amin Abbasi6Alireza Khajavi7Mohammad E. Khamseh8Reza Malekzadeh9Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS)Case Western Reserve University, School of MedicineLiver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical SciencesDigestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical SciencesDigestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical SciencesResearch Center for Prevention of Cardiovascular Diseases, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS)Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS)Student Research Committee, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical ScienceEndocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS)Digestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical SciencesAbstract Background Whether pre-diabetes in the absence of hypertension (HTN) or dyslipidemia (DLP) is a risk factor for occurrence of major adverse cardiovascular events (MACE) is not fully established. We investigated the effect of impaired fasting glucose (IFG) alone and in combination with HTN, DLP or both on subsequent occurrence of MACE as well as individual MACE components. Methods This longitudinal population-based study included 11,374 inhabitants of Northeastern Iran. The participants were free of any cardiovascular disease at baseline and were followed yearly from 2010 to 2017. Cox proportional hazard models were fitted to measure the hazard of IFG alone or in combination with HTN and DLP on occurrence of MACE as the primary endpoint. Results Four hundred thirty-seven MACE were recorded during 6.2 ± 0.1 years follow up. IFG alone compared to normal fasting glucose (NFG) was not associated with an increase in occurrence of MACE (HR, 0.87; 95% CI, 0.19–4.02; p, 0.854). However, combination of IFG and HTN (HR, 2.88; 95% CI, 2.04–4.07; p, 0.000) or HTN + DLP (HR, 2.98; 95% CI, 1.89–4.71; p, 0.000) significantly increased the risk for MACE. Moreover, IFG + DM with or without HTN, DLP, or both was also associated with an increase in the incidence of MACE. Conclusion IFG, per se, does not appear to increase hazard of MACE. However, IFG with HTN or HTN + DLP conferred a significant hazard for MACE in an incremental manner. Moreover, IFG without HTN, adjusted for DLP, can be associated with an increase in the risk for CVD- death.http://link.springer.com/article/10.1186/s12872-020-01390-8Dyslipidemia (DLP)Hypertension (HTN)Impaired fasting glucose (IFG)Major adverse cardiovascular events (MACE)Pre-diabetes (pre-DM) |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Nahid Hashemi Madani Faramarz Ismail-Beigi Hossein Poustchi Mahdi Nalini Sadaf G. Sepanlou Mojtaba Malek Mohammad Amin Abbasi Alireza Khajavi Mohammad E. Khamseh Reza Malekzadeh |
spellingShingle |
Nahid Hashemi Madani Faramarz Ismail-Beigi Hossein Poustchi Mahdi Nalini Sadaf G. Sepanlou Mojtaba Malek Mohammad Amin Abbasi Alireza Khajavi Mohammad E. Khamseh Reza Malekzadeh Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study BMC Cardiovascular Disorders Dyslipidemia (DLP) Hypertension (HTN) Impaired fasting glucose (IFG) Major adverse cardiovascular events (MACE) Pre-diabetes (pre-DM) |
author_facet |
Nahid Hashemi Madani Faramarz Ismail-Beigi Hossein Poustchi Mahdi Nalini Sadaf G. Sepanlou Mojtaba Malek Mohammad Amin Abbasi Alireza Khajavi Mohammad E. Khamseh Reza Malekzadeh |
author_sort |
Nahid Hashemi Madani |
title |
Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study |
title_short |
Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study |
title_full |
Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study |
title_fullStr |
Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study |
title_full_unstemmed |
Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study |
title_sort |
impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the golestan cohort study |
publisher |
BMC |
series |
BMC Cardiovascular Disorders |
issn |
1471-2261 |
publishDate |
2020-03-01 |
description |
Abstract Background Whether pre-diabetes in the absence of hypertension (HTN) or dyslipidemia (DLP) is a risk factor for occurrence of major adverse cardiovascular events (MACE) is not fully established. We investigated the effect of impaired fasting glucose (IFG) alone and in combination with HTN, DLP or both on subsequent occurrence of MACE as well as individual MACE components. Methods This longitudinal population-based study included 11,374 inhabitants of Northeastern Iran. The participants were free of any cardiovascular disease at baseline and were followed yearly from 2010 to 2017. Cox proportional hazard models were fitted to measure the hazard of IFG alone or in combination with HTN and DLP on occurrence of MACE as the primary endpoint. Results Four hundred thirty-seven MACE were recorded during 6.2 ± 0.1 years follow up. IFG alone compared to normal fasting glucose (NFG) was not associated with an increase in occurrence of MACE (HR, 0.87; 95% CI, 0.19–4.02; p, 0.854). However, combination of IFG and HTN (HR, 2.88; 95% CI, 2.04–4.07; p, 0.000) or HTN + DLP (HR, 2.98; 95% CI, 1.89–4.71; p, 0.000) significantly increased the risk for MACE. Moreover, IFG + DM with or without HTN, DLP, or both was also associated with an increase in the incidence of MACE. Conclusion IFG, per se, does not appear to increase hazard of MACE. However, IFG with HTN or HTN + DLP conferred a significant hazard for MACE in an incremental manner. Moreover, IFG without HTN, adjusted for DLP, can be associated with an increase in the risk for CVD- death. |
topic |
Dyslipidemia (DLP) Hypertension (HTN) Impaired fasting glucose (IFG) Major adverse cardiovascular events (MACE) Pre-diabetes (pre-DM) |
url |
http://link.springer.com/article/10.1186/s12872-020-01390-8 |
work_keys_str_mv |
AT nahidhashemimadani impairedfastingglucoseandmajoradversecardiovasculareventsbyhypertensionanddyslipidemiastatusthegolestancohortstudy AT faramarzismailbeigi impairedfastingglucoseandmajoradversecardiovasculareventsbyhypertensionanddyslipidemiastatusthegolestancohortstudy AT hosseinpoustchi impairedfastingglucoseandmajoradversecardiovasculareventsbyhypertensionanddyslipidemiastatusthegolestancohortstudy AT mahdinalini impairedfastingglucoseandmajoradversecardiovasculareventsbyhypertensionanddyslipidemiastatusthegolestancohortstudy AT sadafgsepanlou impairedfastingglucoseandmajoradversecardiovasculareventsbyhypertensionanddyslipidemiastatusthegolestancohortstudy AT mojtabamalek impairedfastingglucoseandmajoradversecardiovasculareventsbyhypertensionanddyslipidemiastatusthegolestancohortstudy AT mohammadaminabbasi impairedfastingglucoseandmajoradversecardiovasculareventsbyhypertensionanddyslipidemiastatusthegolestancohortstudy AT alirezakhajavi impairedfastingglucoseandmajoradversecardiovasculareventsbyhypertensionanddyslipidemiastatusthegolestancohortstudy AT mohammadekhamseh impairedfastingglucoseandmajoradversecardiovasculareventsbyhypertensionanddyslipidemiastatusthegolestancohortstudy AT rezamalekzadeh impairedfastingglucoseandmajoradversecardiovasculareventsbyhypertensionanddyslipidemiastatusthegolestancohortstudy |
_version_ |
1724598779271708672 |